{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-247640","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.290371+00:00","generated_at":"2026-05-30T08:08:14.954440+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits","bullets":["GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.","Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.","2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.","Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-247640","json":"https://secwatch.observer/filing/0001193125-24-247640.json","markdown":"https://secwatch.observer/filing/0001193125-24-247640.md","text":"https://secwatch.observer/filing/0001193125-24-247640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/0001193125-24-247640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524247640/d117946d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:08:14.954440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}